SCHEMBL21551603

SCHEMBL21551603

COCCN(Cc1cc(Oc2ccc(N3CCC(N(C)C(=O)OC(C)(C)C)CC3)nc2)cc(-c2cc(Cl)cc(Cl)c2)c1)C(=O)O

nearest known ligand 0.39

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ FURIN P09958 6/20 0.39
▸ RET P07949 2/20 0.36
▸ MCHR1 Q99705 4/20 0.35
▸ AAK1 Q2M2I8 1/20 0.35
▸ PDE10A Q9Y233 1/20 0.34
▸ PIK3CD O00329 1/20 0.33
▸ CHRM4 P08173 1/20 0.33
▸ CKS1B P61024 1/20 0.32
▸ SKP1 P63208 1/20 0.32
▸ SKP2 Q13309 1/20 0.32
▸ GPR119 Q8TDV5 1/20 0.32
▸ HRH3 Q9Y5N1 1/20 0.32
▸ PPARA Q07869 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29890855 0.96 FURIN (0.39) FURINRETMCHR1AAK1PDE10A
SCHEMBL29890682 0.91 FURIN (0.37) FURINRETMCHR1AAK1PDE10A
SCHEMBL21551605 0.84 FURIN (0.41) FURINRETMCHR1AAK1PIK3CD
SCHEMBL28546916 0.82 MCHR1 (0.40) FURINRETMCHR1AAK1PDE10A
SCHEMBL28551717 0.82 MCHR1 (0.41) FURINRETMCHR1AAK1PDE10A
SCHEMBL21564562 0.77 CKS1B (0.44) FURINRETCKS1BSKP1SKP2
SCHEMBL21551013 0.77 CKS1B (0.46) FURINRETCKS1BSKP1SKP2
SCHEMBL29890729 0.77 CKS1B (0.44) FURINRETCKS1BSKP1SKP2
SCHEMBL27044993 0.72 GPR119 (0.54) RETCKS1BSKP1SKP2GPR119
SCHEMBL30931855 0.71 HTR2C (0.35) MCHR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3790871-B1 FURIN INHIBITORS GLAXOSMITHKLINE IP DEV LTD (GB) 2024-01-24 — — EP disclosed
US-11773078-B2 Furin inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2023-10-03 — — US disclosed
US-20220315556-A1 FURIN INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2022-10-06 — — US disclosed
EP-3790871-A1 FURIN INHIBITORS GlaxoSmithKline Intellectual Property Development Limited (GB) 2021-03-17 — — EP disclosed
WO-2019215341-A1 FURIN INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2019-11-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220315556-A1 FURIN INHIBITORS FURIN, TGFB1, PCSK7 FURIN 1/4885RET 1057/4885MCHR1 2272/4885
US-11773078-B2 Furin inhibitors FURIN, TGFB1, PCSK7 FURIN 1/4885RET 1057/4885MCHR1 2272/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback